Wir sind mit live! Mehr erfahren

Haemonetics

HAE

Börsenwert 5,38 Mrd. $

118,28 USD

-3,01

2,48 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

118,52

+0,24

0,2 %

1 Tag

-2,48 %

5 Tage

-0,35 %

1 Monat

11,33 %

3 Monate

50,68 %

6 Monate

96,77 %

Seit Jahresbeginn

47,89 %

1 Jahr

137,65 %

5 Jahre

76,35 %

10 Jahre

243,14 %

Profil: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

Mitarbeiter: 3.009

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 59,3 %

Neutral 29,6 %

Negativ 11,1 %

Zacks Investment Research

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?

HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?

Zacks Investment Research

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?

HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?

Zacks Investment Research

Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term

Zacks Investment Research

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?

Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?

Proactive Investors

Haemonetics shares jump as CSL sets 2027 rollout of plasma devices

Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable for moving its US plasma collection centers onto the company's devices. CSL Limited (ASX:CSL), the Australian biotechnology company, expects to finish rolling out Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of 2027.

Haemonetics shares jump as CSL sets 2027 rollout of plasma devices

Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue

CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.

Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue

Zacks Investment Research

PAHC vs. HAE: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?

PAHC vs. HAE: Which Stock Is the Better Value Option?

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026

BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026.

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026

Zacks Investment Research

Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Investment Research

PAHC vs. HAE: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?

PAHC vs. HAE: Which Stock Should Value Investors Buy Now?

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt